首页> 外文期刊>Neuromodulation: journal of the International Neuromodulation Society >New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial
【24h】

New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial

机译:难治性慢性力学低腰部疼痛恢复性神经刺激的新疗法,以激活腰部多腹部:一年的前瞻性多中心临床试验结果

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: The purpose of the international multicenter prospective single arm clinical trial was to evaluate restorative neurostimulation eliciting episodic contraction of the lumbar multifidus for treatment of chronic mechanical low back pain (CMLBP) in patients who have failed conventional therapy and are not candidates for surgery or spinal cord stimulation (SCS). Materials and Methods: Fifty-three subjects were implanted with a neurostimulator (ReActiv8, Mainstay Medical Limited, Dublin, Ireland). Leads were positioned bilaterally with electrodes close to the medial branch of the L2 dorsal ramus nerve. The primary outcome measure was low back pain evaluated on a 10-Point Numerical Rating Scale (NRS). Responders were defined as subjects with an improvement of at least the Minimal Clinically Important Difference (MCID) of = 2-point in low back pain NRS without a clinically meaningful increase in LBP medications at 90 days. Secondary outcome measures included Oswestry Disability Index (ODI) and Quality of Life (QoL; EQ-5D). Results: For 53 subjects with an average duration of CLBP of 14 years and average NRS of 7 and for whom no other therapies had provided satisfactory pain relief, the responder rate was 58%. The percentage of subjects at 90 days, six months, and one year with = MCID improvement in single day NRS was 63%, 61%, and 57%, respectively. Percentage of subjects with = MCID improvement in ODI was 52%, 57%, and 60% while those with = MCID improvement in EQ-5D was 88%, 82%, and 81%. There were no unanticipated adverse events (AEs) or serious AEs related to the device, procedure, or therapy. The initial surgical approach led to a risk of lead fracture, which was mitigated by a modification to the surgical approach.
机译:目标:国际多中心前瞻性单臂临床试验的目的是评估腰椎多颌骨刺激的恢复性神经刺激,以治疗常规治疗失败的患者慢性机械低腰(CMLBP),并且不是手术的候选者脊髓刺激(SCS)。材料和方法:将五十三个受试者植入NeurostImulimulator(Reactiv8,Hainstay Medical Limited,Dublin,Ireland)。通过靠近L2背拉心神经的内侧分支的电极定位,电极定位。主要结果测量对10分额定值(NRS)进行评估的低疼痛。响应者被定义为受试者,改善至少最小的临床重要差异(MCID)的& =低腰疼痛NRS的2点,在90天内没有临床有意义的LBP药物增加。二次结果措施包括Oswestry残疾指数(ODI)和生活质量(QOL; EQ-5D)。结果:53个受试者平均持续时间为14岁的CLBP,平均NR为7,而且没有其他疗法提供令人满意的疼痛缓解,响应率为58%。在90天,六个月和一年内的受试者的百分比分别为& =单日NRS的MCID改善分别为63%,61%和57%。 ODI的MCID改善的百分比为52%,57%和60%,而EQ-5D的MCID改善为88%,82%和81%。与设备,程序或治疗有关的意外不良事件(AES)或严重的AES。初始手术方法导致铅骨折的风险,通过对外科手术方法的修改来减轻。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号